Streetbeat News

ORYZF

Oryzon Genomics S.A.

https://www.oryzon.com/

CEO

Carlos Manuel Buesa Arjol

Industry

Research and Development in Biotechnology

Open

3.10

Mkt cap

201M

Volume

15K

High

3.10

P/E Ratio

-44.29

52-wk high

3.10

Low

3.10

Div yield

N/A

52-wk low

1.41

Oryzon Genomics, a clinical-stage biopharmaceutical company, will provide updates on its corporate progress at several international events in March and April.

Portfolio Pulse from

March 14, 2025 | 12:15 pm

Oryzon Genomics has published a study on Phelan-McDermid Syndrome (PMS) patients, which could lead to a personalized medicine approach using vafidemstat. This study is a step towards a precision psychiatry clinical trial.

Portfolio Pulse from

March 05, 2025 | 1:15 pm

Oryzon Genomics, a clinical-stage biopharmaceutical company, reported its financial results for Q4 2024 and provided a corporate update. The company focuses on developing therapies using epigenetics for diseases with unmet medical needs.

Portfolio Pulse from

February 27, 2025 | 9:15 pm

Oryzon Genomics announced the publication of final Phase IIa REIMAGINE study results in Psychiatry and Clinical Neurosciences, evaluating vafidemstat's safety and efficacy in treating aggression in BPD, ADHD, and ASD patients.

Portfolio Pulse from

February 14, 2025 | 1:15 pm

Oryzon Genomics, a clinical-stage biopharmaceutical company, plans to reshape its Board of Directors by adding four new members at the upcoming Shareholders' Meeting on February 28.

Portfolio Pulse from

January 27, 2025 | 2:45 pm

Oryzon Genomics, a clinical-stage biopharmaceutical company, will provide updates on its corporate progress at several international events in January and February.

Portfolio Pulse from

January 10, 2025 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.